> Details

Díaz-González, Álvaro; Hernández-Guerra, Manuel; Pérez-Medrano, Indhira; Sapena, Víctor; Riveiro-Barciela, Mar; Barreira-Díaz, Ana; Gómez, Elena; Morillas, Rosa M; Del Barrio, María; Escudé, Laia; Mateos, Beatriz; Horta, Diana; Gómez, Judith; Conde, Isabel; Ferre-Aracil, Carlos; El Hajra, Ismael; Arencibía, Ana; Zamora, Javier; Fernández, Ainhoa; Salcedo, Magdalena; Molina, Esther; Soria, Anna; Estévez, Pamela; López, Carmen; [...]

Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
  • Contributor: Díaz-González, Álvaro; Hernández-Guerra, Manuel; Pérez-Medrano, Indhira; Sapena, Víctor; Riveiro-Barciela, Mar; Barreira-Díaz, Ana; Gómez, Elena; Morillas, Rosa M; Del Barrio, María; Escudé, Laia; Mateos, Beatriz; Horta, Diana; Gómez, Judith; Conde, Isabel; Ferre-Aracil, Carlos; El Hajra, Ismael; Arencibía, Ana; Zamora, Javier; Fernández, Ainhoa; Salcedo, Magdalena; Molina, Esther; Soria, Anna; Estévez, Pamela; López, Carmen; [...]
  • imprint: Ovid Technologies (Wolters Kluwer Health), 2023
  • Published in: Hepatology
  • Language: English
  • DOI: 10.1097/hep.0000000000000018
  • ISSN: 0270-9139
  • Origination:
  • Footnote:
  • Description: <jats:sec> <jats:title>Background and Aims:</jats:title> <jats:p>In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options.</jats:p> </jats:sec> <jats:sec> <jats:title>Approach and Results:</jats:title> <jats:p>This was a retrospective, multicenter study of 105 naive AIH patients treated with budesonide as the first-line drug. The control group included 276 patients treated with prednisone. Efficacy was assessed using logistic regression and validated using inverse probability of treatment weighting propensity score. The median time to biochemical response (BR) was 3.1 months in patients treated with budesonide and 4.9 months in those with prednisone. The BR rate was significantly higher in patients treated with prednisone (87% vs. 49% of patients with budesonide, <jats:italic toggle="yes">p</jats:italic> &lt; 0.001). The probability of achieving BR, assessed using the inverse probability of treatment weighting propensity score, was significantly lower in the budesonide group (OR = 0.20; 95% CI: 0.11–0.38) at any time during follow-up, and at 6 (OR = 0.51; 95% CI: 0.29–0.89) and 12 months after starting treatment (0.41; 95% CI: 0.23–0.73). In patients with transaminases &lt;2 × upper limit of normal, BR was similar in both treatment groups. Prednisone treatment was significantly associated with a higher risk of adverse events (24.2% vs. 15.9%, <jats:italic toggle="yes">p</jats:italic> = 0.047).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>In the real-life setting, the use of budesonide as first-line treatment is low, and it is generally prescribed to patients with perceived less disease activity. Budesonide was inferior to prednisone as a first-line drug but was associated with fewer side effects.</jats:p> </jats:sec>
  • Access State: Open Access